English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The fight against this pandemic needs simultaneous use of effective preventive action and wider access to treatment. However, in the absence of vaccine, fighting activities focus firstly on prevention through awareness of infection status and secondly on a better therapeutic management of infected persons. Given its importance in struggling against AIDS, biological diagnosis of HIV infection is importance and is based on the detection of antibodies in adults and children over 18 months. The “conventional” strategy associates antibody screening by one or more enzyme-linked immunosorbent assays (ELISA), and a confirmation of positive results with Western blot. This strategy is not always feasible in developing countries for many reasons. Indeed, this strategy The PBEIA uses peptides representative of the immunodominant regions of the transmembrane glycoprotein and the surface glycoprotein (V3 loop) of both HIV-1 (gp41 and V3.1) and HIV-2 (gp36 and V3.2). The evaluation of this assay was carried out using: 510 serum samples including 200 from HIV-negative individuals and 310 from HIV-positive individuals (130 HIV-1,105 HIV-2 and 75 HIV with dual seroreactivity) based on results obtained and 145 other samples positive for HIV-2. Murex HIV-1.2.OTM, Vironostika HIV Uni-Form II plus OTM and western blot tests were used as reference gold standard assays.

Field Evaluation and Use of a Non Commercial Peptide Enzyme Immunoassay for Human Immunodeficiency Virus Serotyping in Abidjan (Ivory Coast)